未登录 Outcomes in Patients with FLT3-Mutated Relapsed/Refractory Acute Myelogenous Leukemia Who Underwent Transplantation in the Phase 3 ADMIRAL Trial of Gilteritinib versus Salvage Chemotherapy 在Gilteritinib与挽救性化疗的3期ADMIRAL试验中接受移植的FLT3-Mutated复发/难治性急性骨髓性白血病患者的结局 Perl, Alexander E.; Larson, Richard A.; Podoltsev, Nikolai A.; Strickland, Stephen; Wang, Eunice S.; Atallah, Ehab; Schiller, GaryJ.; Martinelli, Giovanni; Neubauer, Andreas; Sierra, Jorge; Montesinos, Pau; Recher, Christian; Yoon, Sung-Soo; Maeda, Yoshinobu; Hosono, Naoko; Onozawa, Masahiro; Kato, Takayasu; Kim, Hee-Je; Hasabou, Nahla; Nuthethi, Rishita; Tiu, Ramon; Levis, Mark J. 分享 收藏
Clinical outcomes in patients with relapsed/refractory FLT3-mutated acute myeloid leukemia treated with gilteritinib who received prior midostaurin or sorafenib Perl, Alexander E.; Hosono, Naoko; Montesinos, Pau; Podoltsev, Nikolai; Martinelli, Giovanni; Panoskaltsis, Nicki; Recher, Christian; Smith, Catherine C.; Levis, Mark J.; Strickland, Stephen; Rollig, Christoph; Gross-Langenhoff, Marco; Chou, Wen-Chien; Lee, Je-Hwan; Yokoyama, Hisayuki; Hasabou, Nahla; Lu, Qiaoyang; Tiu, Ramon, V; Altman, Jessica K. 分享 收藏
ERK Inhibitor LY3214996-Based Treatment Strategies for RAS-Driven Lung Cancer Kohler, Jens; Zhao, Yutong; Li, Jiaqi; Gokhale, Prafulla C.; Tiv, Hong L.; Knott, Aine R.; Wilkens, Margaret K.; Soroko, Kara M.; Lin, Mika; Ambrogio, Chiara; Musteanu, Monica; Ogino, Atsuko; Choi, Jihyun; Bahcall, Magda; Bertram, Arrien A.; Chambers, Emily S.; Paweletz, Cloud P.; Bhagwat, Shripad, V; Manro, Jason R.; Tiu, Ramon, V; Janne, Pasi A. 分享 收藏
Clinical Characteristics, Treatments, and Concurrent Mutations in Non-Small Cell Lung Cancer Patients With NF1 Mutations Bowman, Lee; Tiu, Ramon; Smyth, Emily Nash; Willard, Melinda Dale; Li, Li; Beyrer, Julie; Han, Yimei; Singh, Ambrish 分享 收藏
Low-Dose Vertical Inhibition of the RAF-MEK-ERK Cascade Causes Apoptotic Death of KRAS Mutant Cancers Raf-mek-erk级联的低剂量垂直抑制导致KRAS突变型癌症的凋亡死亡 Ozkan-Dagliyan, Irem; Diehl, J. Nathaniel; George, Samuel D.; Schaefer, Antje; Papke, Bjoern; Klotz-Noack, Kathleen; Waters, Andrew M.; Goodwin, Craig M.; Gautam, Prson; Pierobon, Mariaelena; Peng, Sen; Gilbert, Thomas S. K.; Lin, Kevin H.; Dagliyan, Onur; Wennerberg, Krister; Petricoin, Emanuel F., III; Tran, Nhan L.; Bhagwat, Shripad, V; Tiu, Ramon, V; Peng, Sheng-Bin; Herring, Laura E.; Graves, Lee M.; Sers, Christine; Wood, Kris C.; Cox, Adrienne D.; Der, Channing J. 分享 收藏
Evaluation of ERK as a therapeutic target in acute myelogenous leukemia (vol 13, pg 234, 2020) Weisberg, Ellen; Meng, Chengcheng; Case, Abigail; Sattler, Martin; Tiv, Hong L.; Gokhale, Prafulla C.; Buhrlage, Sara; Wang, Jinhua; Gray, Nathanael; Stone, Richard; Liu, Suiyang; Bhagwat, Shripad V.; Tiu, Ramon V.; Adamia, Sophia; Griffin, James D. 分享 收藏
ERK Inhibitor LY3214996 Targets ERK Pathway-Driven Cancers: A Therapeutic Approach Toward Precision Medicine Bhagwat, Shripad V.; McMillen, William T.; Cai, Shufen; Zhao, Baohui; Whitesell, Matthew; Shen, Weihua; Kindler, Lisa; Flack, Robert S.; Wu, Wenjuan; Anderson, Bryan; Zhai, Yan; Yuan, Xiu-Juan; Pogue, Meghann; Van Horn, Robert D.; Rao, Xi; McCann, Denis; Dropsey, Andrew J.; Manro, Jason; Walgren, Jennie; Yuen, Eunice; Rodriguez, Michael J.; Plowman, Gregory D.; Tiu, Ramon V.; Joseph, Sajan; Peng, Sheng-Bin 分享 收藏
A Phase I Study of LY3009120, a Pan-RAF Inhibitor, in Patients with Advanced or Metastatic Cancer Sullivan, Ryan J.; Hollebecque, Antoine; Flaherty, Keith T.; Shapiro, Geoffrey I.; Ahnert, Jordi Rodon; Millward, Michael J.; Zhang, Wei; Gao, Ling; Sykes, Amanda; Willard, Melinda D.; Yu, Danni; Schade, Andrew E.; Crowe, KrisAnne; Flynn, Daniel L.; Kaufman, Michael D.; Henry, James R.; Peng, Sheng-Bin; Benhadji, Karim A.; Conti, Ilaria; Gordon, Michael S.; Tiu, Ramon V.; Hong, David S. 分享 收藏
Evaluation of ERK as a therapeutic target in acute myelogenous leukemia Weisberg, Ellen; Meng, Chengcheng; Case, Abigail; Sattler, Martin; Tiv, Hong L.; Gokhale, Prafulla C.; Buhrlage, Sara; Wang, Jinhua; Gray, Nathanael; Stone, Richard; Liu, Suiyang; Bhagwat, Shripad V.; Tiu, Ramon V.; Adamia, Sophia; Griffin, James D. 分享 收藏
分享 收藏
Identification and characterization of LY3410738, a novel covalent inhibitor of cancer-associated mutant Isocitrate Dehydrogenase 1 (IDH1) Brooks, Nathan; DeWalt, Robin; Boulet, Serge; Lu, ZhaoHai; Kays, Lisa; Cavitt, Rachel; Gomez, Sandra; Strelow, John; Milligan, Paul; Roth, Kenneth; Bauer, Renato; Antonysamy, Stephen; Hahn, Patric; Rankovic, Zoran; McCann, Denis; Mo, Gary; Tiu, Ramon; Burkholder, Timothy; Geeganage, Sandaruwan; Gilmour, Raymond 分享 收藏
Inhibition of ERK by LY3214996 augments nab-paclitaxel and gemcitabine combination chemotherapy efficacy in preclinical models of pancreatic cancer Bhagwat, Shripad V.; Wu, Wenjuan; Zhao, Baohui; Shen, Weihua; Kindler, Lisa; Stephens, Jennifer; Manro, Jason; McMillen, William; Joseph, Sajan; Peng, Sheng-Bin; Tiu, Ramon V. 分享 收藏
Combination of an ERK1/2 inhibitor (LY3214996) with VEGFR-2 inhibitor enhances anti-tumor activity in KRAS mutant non-small cell lung cancer Wu, Wenjuan; Bhagwat, Shripad V.; Jones, Bonita D.; Swearingen, Michelle L.; Falcon, Beverly L.; McMillen, William T.; Joseph, Sajan; Buchanan, Sean; Peng, Sheng-Bin; Reinhard, Christoph; Tiu, Ramon V. 分享 收藏
Efficacy of the ERK inhibitor LY3214996 and the PI3K/mTOR inhibitor LY3023414 in patient-derived RAS-mutant NSCLC models Kohler, Jens; Gokhale, Prafulla C.; Li, Jiaqi; Wilkens, Margaret K.; Tiv, Hong; Bhagwat, Shripad V.; Donoho, Greg; Brueck, Patrick; Tiu, Ramon V.; Redig, Amanda J.; Chambers, Emily S.; Ogino, Atsuko; Choi, Jihyun; Xu, Man; Kirschmeier, Paul; Janne, Pasi A. 分享 收藏
Phase I Study of LY2940680, a Smo Antagonist, in Patients with Advanced Cancer Including Treatment-Naive and Previously Treated Basal Cell Carcinoma Bendell, Johanna; Andre, Valerie; Ho, Alan; Kudchadkar, Ragini; Migden, Michael; Infante, Jeffrey; Tiu, Ramon V.; Pitou, Celine; Tucker, Trevor; Brail, Les; Von Hoff, Daniel 分享 收藏
Loss of epigenetic regulator TET2 and oncogenic KIT regulate myeloid cell transformation via PI3K pathway Palam, Lakshmi Reddy; Mali, Raghuveer Singh; Ramdas, Baskar; Srivatsan, Sridhar Nonavinkere; Visconte, Valeria; Tiu, Ramon V.; Vanhaesebroeck, Bart; Roers, Axel; Gerbaulet, Alexander; Xu, Mingjiang; janga, Sarath Chandra; Takemoto, Clifford M.; Paczesny, Sophie; Kapur, Reuben 分享 收藏
RAF inhibitor LY3009120 sensitizes RAS or BRAF mutant cancer to CDK4/6 inhibition by abemaciclib via superior inhibition of phospho-RB and suppression of cyclin D1 Chen, S-H; Gong, X.; Zhang, Y.; Van Horn, R. D.; Yin, T.; Huber, L.; Burke, T. F.; Manro, J.; Iversen, P. W.; Wu, W.; Bhagwat, S. V.; Beckmann, R. P.; Tiu, R. V.; Buchanan, S. G.; Peng, S-B 分享 收藏
Mouse PDX Trial Suggests Synergy of Concurrent Inhibition of RAF and EGFR in Colorectal Cancer with BRAF or KRAS Mutations Yao, Yung-mae M.; Donoho, Gregory P.; Iversen, Philip W.; Zhang, Youyan; Van Horn, Robert D.; Forest, Amelie; Novosiadly, Ruslan D.; Webster, Yue Wang; Ebert, Philip; Bray, Steven; Ting, Jason C.; Aggarwal, Amit; Henry, James R.; Tiu, Ramon V.; Plowman, Gregory D.; Peng, Sheng-Bin 分享 收藏
Combination of a novel ERK1/2 inhibitor (LY3214996) with CDK4 and CDK6 inhibitor (abemaciclib) enhances antitumor efficacy in KRAS mutant non-small cell lung cancer (NSCLC) Wu, Wenjuan; Bhagwat, Shripad V.; King, Constance; Pratt, Susan; Gong, Xueqian; Stewart, Julie; Jones, Bonita; Flack, Robert; Beckman, Richard; Falcon, Beverly; Manro, Jason; McMillen, William T.; Tiu, Ramon V.; Peng, Sheng-Bin; Reinhard, Christoph; Joseph, Sajan; Buchanan, Sean 分享 收藏
Discovery of LY3214996, a selective and novel ERK1/2 inhibitor with potent antitumor activities in cancer models with MAPK pathway alterations Bhagwat, Shripad V.; McMillen, William T.; Cai, Shufen; Zhao, Baohui; Whitesell, Matthew; Kindler, Lisa; Flack, Robert S.; Wu, Wenjuan; Huss, Karen; Anderson, Bryan; Yuan, Xiu-Juan; Jaken, Susan; McCann, Denis; Mathes, Brian; Dropsey, Andrew J.; Manro, Jason; Walgren, Jennie; Yuen, Eunice; Gong, Xueqian; Rodriguez, Michael J.; Huang, Jianping; Tiu, Ramon V.; Joseph, Sajan; Peng, Sheng-Bin 分享 收藏
未登录.png){kind=icon}
.png){kind=icon}
.png){kind=icon}
.png){kind=icon}
.png){kind=icon}
.png){kind=icon}
